Clinical Trials Logo

Metastatic Sarcoma clinical trials

View clinical trials related to Metastatic Sarcoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05448820 Active, not recruiting - Soft Tissue Sarcoma Clinical Trials

YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Start date: November 14, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open label, Phase 1/2 study of YH001 initially given in combination with envafolimab, and then given in combination with envafolimab plus doxorubicin in patients with advanced or metastatic sarcoma, followed by Phase 2 cohorts of patients with select histologies of advanced or metastatic sarcoma.

NCT ID: NCT04595747 Active, not recruiting - Metastatic Sarcoma Clinical Trials

Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

Start date: May 3, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of rogaratinib in treating patients with sarcoma with a change in a group of proteins called fibroblast growth factor receptors (FGFRs) or SDH-deficient gastrointestinal stromal tumor (GIST). Rogaratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.